Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation.

Abstract

Nimodipine is an L-type calcium channel blocker and is used to treat vasospasm in patients with subarachnoid hemorrhage. Its putative mechanism of action is relaxation of smooth muscle cells in cerebral arteries. In addition, nimodipine may have pleiotropic effects against vasospasm. Systemic hypotension is an adverse effect when patients are treated with oral or intravenous nimodipine. Intracranial administration of nimodipine formulations may produce higher concentration of nimodipine in the cerebrospinal fluid (CSF) than is possible to achieve orally or intravenously, while resulting in lower incidence of systemic hypotension. The aim of this study was to provide information on plasma and CSF levels of nimodipine in beagle dogs as a comparative data for development of experimental intracranial treatment modalities. Plasma levels of nimodipine were measured after current 30 and 60mg single oral dose of nimodipine (Nimotop(®) 30mg tablets), a single intravenous bolus 0.72mg/dog of nimodipine (Nimotop(®) 0.2mg/ml infusion solution) and CSF levels after 60mg single oral dose of nimodipine. CSF/Plasma concentration ratio of nimodipine after oral administration of 60mg at 1h was 0.013±0.0005. The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72mg was 1.8h and mean plasma clearance was 40.3 and 3.4l/h/kg. Absolute bioavailability was 22%. Maximum plasma concentration and area under the plasma concentration-time curve from time of administration until the last measurable plasma concentration increased in a dose-proportional manner comparing the exposure parameters at oral doses of 30 and 60mg. Individual variation in the kinetic profile of nimodipine was measured.